Abstract Number: 1897 • 2017 ACR/ARHP Annual Meeting
the Ferritin to ESR Ratio: A Simple Measure to Distinguish Macrophage Activation Syndrome from Systemic Arthritis Flare
Background/Purpose: Macrophage activation syndrome (MAS) is a life threatening complication of systemic juvenile idiopathic arthritis (sJIA). As MAS often shares clinical and laboratory features with…Abstract Number: 1898 • 2017 ACR/ARHP Annual Meeting
Overweight/Obesity Affect Histological Features of Synovial Membrane of Rheumatoid Arthritis Patients from Disease Onset to Stable Remission Achievement
Background/Purpose: Despite animal models, little is known about synovial tissue (ST) composition of overweight/obese Rheumatoid Arthritis patients. The aim of the study was to investigate…Abstract Number: 1899 • 2017 ACR/ARHP Annual Meeting
Osteopontin and Leptin Are Associated with Erosive Disease in an Inception Cohort of Rheumatoid Arthritis Treated-to-Target with Combination Conventional DMARD Therapy
Background/Purpose: We sought to identify biomarkers associated with erosive disease and bone loss in an inception rheumatoid arthritis (RA) cohort receiving treat-to-target combination DMARD therapy…Abstract Number: 1900 • 2017 ACR/ARHP Annual Meeting
Effect of Age and Body Mass Index (BMI) on Multi-Biomarker Disease Activity (MBDA) Score in Patients with Rheumatoid Arthritis
Background/Purpose: We evaluated the associations between MBDA score and age and between MBDA score and BMI in patients with rheumatoid arthritis (RA). These relationships may…Abstract Number: 1901 • 2017 ACR/ARHP Annual Meeting
Unfavorable Body Composition Already at the Onset of Clinical Arthritis
Background/Purpose: An unfavorable body composition is often present in chronic arthritis patients. This unfavorable composition is a loss of muscle mass (sarcopenia), with a stable…Abstract Number: 1902 • 2017 ACR/ARHP Annual Meeting
A Pattern of Higher Serum Levels of IL-10 and MMP-3, Along with Lower IL-6R, Identify RA Patients with Interstitial Lung Disease
Background/Purpose: The pathogenesis and prediction of RA-associated interstitial lung disease (ILD), an extra-articular manifestation with high morbidity and mortality, is poorly understood. We explored the…Abstract Number: 1903 • 2017 ACR/ARHP Annual Meeting
Can Achieving Sustained DAS Remission Prevent Arterial Stiffness Progression in Early Rheumatoid Arthritis – a Post-Hoc Analysis of a Randomized Controlled Study
Background/Purpose: Patients with rheumatoid arthritis (RA) have a higher incidence of cardiovascular disease (CVD) and prevalence of arterial stiffness (AS) due to chronic inflammation. AS…Abstract Number: 1904 • 2017 ACR/ARHP Annual Meeting
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study of Upadacitinib (ABT-494), a Selective JAK-1 Inhibitor, in Patients with Active Rheumatoid Arthritis with Inadequate Response to Conventional Synthetic Dmards
Background/Purpose: Upadacitinib (UPA) is an oral, selective JAK-1 inhibitor in development for the treatment of patients (pts) with moderate to severe rheumatoid arthritis (RA) and…Abstract Number: 1905 • 2017 ACR/ARHP Annual Meeting
Sustained Response Following Discontinuation of Methotrexate in Patients with Rheumatoid Arthritis Treated with Subcutaneous Tocilizumab: Results from a Randomized Controlled Trial
Background/Purpose: Although methotrexate (MTX) is often administered in combination with biologics for the treatment of rheumatoid arthritis (RA), it may be discontinued due to intolerance…Abstract Number: 1906 • 2017 ACR/ARHP Annual Meeting
Tofacitinib with and without Methotrexate Versus Adalimumab with Methotrexate for the Treatment of Rheumatoid Arthritis: Patient-Reported Outcomes from a Phase 3b/4 Randomized Trial
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We compared patient-reported outcomes (PROs) among patients receiving tofacitinib monotherapy,…Abstract Number: 1907 • 2017 ACR/ARHP Annual Meeting
Safety, Pharmacokinetics, and Efficacy of E6011, an Anti-Fractalkine Monoclonal Antibody, in a First-in-Patient Phase 1/2 Study on Rheumatoid Arthritis: 52-Week Results
Background/Purpose: Fractalkine (CX3CL1/FKN) is a chemokine that regulates chemotaxis and adhesion of CX3C chemokine receptor 1 (CX3CR1)-expressing inflammatory cells. We previously presented the interim results…Abstract Number: 1908 • 2017 ACR/ARHP Annual Meeting
Long-Term Efficacy and Safety Results of a Global Phase 3 Trial of Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, in Patients with Active Rheumatoid Arthritis Despite Disease-Modifying Anti-Rheumatic Drug Treatment
Background/Purpose: In patients (pts) with active rheumatoid arthritis (RA) despite DMARD treatment, sirukumab, a human monoclonal antibody that selectively binds to the IL-6 cytokine with…Abstract Number: 1909 • 2017 ACR/ARHP Annual Meeting
Long Term Safety of Filgotinib in the Treatment of Rheumatoid Arthritis: Week 84 Data from a Phase 2b Open-Label Extension Study
Background/Purpose: Filgotinib is an orally administered, selective inhibitor of Janus Kinase 1 (JAK1) currently in Phase 3 development for the treatment of rheumatoid arthritis (RA).…Abstract Number: 1910 • 2017 ACR/ARHP Annual Meeting
ERAP1 Deficiency Implicates Long Peptides in Protection from HLA-B27-Induced Experimental Spondyloarthritis
Background/Purpose: Common endoplasmic reticulum (ER) aminopeptidase 1 (ERAP1) haplotypes influence the risk of developing axial spondyloarthritis (SpA) in HLA-B27-positive individuals, with loss-of-function and reduced expression…Abstract Number: 1911 • 2017 ACR/ARHP Annual Meeting
Impaired Control of Autoreactive T Cell Expansion Is Coupled with Type-1 Regulatory T Cell Deficiency in BALB/c ZAP70W163C Mutant Mice
Background/Purpose: In the context of reduced TCR signaling in the BALB/c ZAP70W163C mutant (SKG) mouse, development of arthritis, psoriasis-like skin inflammation and ileitis after intra-peritoneal…
ACR Meeting Abstracts